New therapies for castrate-resistant prostate cancer

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Mohler JL, Gregory CW, FOre. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8
   PubMed Web of Science ®Google Scholar
• Linja MJ, Savinainen KJ, Saramaki OR, Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, Gene expression of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Halabi S, Conaway M, Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13
   PubMed Web of Science ®Google Scholar
• Tannock IF, Osoba D, Stockler MR, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, de Wit R, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study. J Clin Oncol 2008;26:242-5
   PubMed Web of Science ®Google Scholar
• Attard G, Belledegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96:1241-6
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997;62:133-42
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AHM, Yap TA, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drive. J Clin Oncol 2008;26:4563-71
   PubMed Web of Science ®Google Scholar
• Ryan C, Smith MR, Fong L, Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AHM, A'Hern R, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8
   PubMed Web of Science ®Google Scholar
• Reid AHM, Attard G, Danila DC, Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501
   PubMed Web of Science ®Google Scholar
• Molina A, Belledegrun AS. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011;185:787-94
   PubMed Web of Science ®Google Scholar
• Scher HI, Logothetis C, Molina A, Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. J Clin Oncol 2011;29(7 Suppl):1995-2005
   Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1 – 2 study. Lancet 2010;375:1437-46
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol 2010;17:S72-9
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-4
   PubMed Web of Science ®Google Scholar
• Attard G, Greystroke A, Kaye S, De Bono JS. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54:72-84
   PubMedGoogle Scholar
• Aller AW, Kraus LA, Bissery M-C. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines. Proc Am Assoc Cancer Res 2000;41:259-68
   Google Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• Pal SK, Twardowski P, Josephson DY. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways. Maturitas 2009;64:61-6
   PubMed Web of Science ®Google Scholar
• Attar RM, Balog AJ, Chen J, Preclinical assessment of gene expression and proteomic profiles promoted by the novel antiandrogen BMS-641988, bicalutamide and castration. AACR Meeting Abstr 2006;2006:1254
   Google Scholar
• Dreicer R, Agus DB, MacVicar GR, Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. Genitourin Cancer Symp Proc 2010;89:103
   Google Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001-11
   PubMed Web of Science ®Google Scholar
• Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010;363:479-81
   PubMed Web of Science ®Google Scholar